theMednetRegister
  • Community
    • Overview
    • Experts
    • Editors
    • Fellows
    • Code of conduct
    • AI Guidelines for Physicians
  • Company
    • About Us
    • FAQs
    • Privacy Policy
    • Terms of Use
    • Careers
    • Programs
  • News
    • News Releases
    • Press Coverage
    • Publications
    • Blog
  • Contact Us
  • Sign in

Hematology

Anifrolumab   

Questions discussed in this category


Would you consider anifrolumab in the management of hematologic manifestations in SLE?
2 Answers available
13193


Papers discussed in this category


N Engl J Med, 2019 Dec 18
Trial of Anifrolumab in Active Systemic Lupus Erythematosus.

Ann Rheum Dis, 2022 Mar 25
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.

Lupus science & medicine, 2018
Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE.

Arthritis Rheum,
Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.

Related Topics in Hematology

  • Lung Cancer
  • Breast Cancer
  • Head and Neck Cancers
  • Hematologic Malignancies
  • Radiation Oncology
  • Gynecologic Oncology
  • Palliation
  • Neuro-Oncology
  • Gastrointestinal Cancers
  • Genitourinary Cancers

Copyright © 2025 theMednet
All Rights Reserved.